Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.

Guerlavais, Vincent et al.·Journal of medicinal chemistry·2023·
RPEP-069252023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.
Published In:
Journal of medicinal chemistry, 66(14), 9401-9417 (2023)
Database ID:
RPEP-06925

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06925·https://rethinkpeptides.com/research/RPEP-06925

APA

Guerlavais, Vincent; Sawyer, Tomi K; Carvajal, Luis; Chang, Yong S; Graves, Bradford; Ren, Jian-Guo; Sutton, David; Olson, Karen A; Packman, Kathryn; Darlak, Krzysztof; Elkin, Carl; Feyfant, Eric; Kesavan, Kamala; Gangurde, Pranoti; Vassilev, Lyubomir T; Nash, Huw M; Vukovic, Vojislav; Aivado, Manuel; Annis, D Allen. (2023). Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.. Journal of medicinal chemistry, 66(14), 9401-9417. https://doi.org/10.1021/acs.jmedchem.3c00623

MLA

Guerlavais, Vincent, et al. "Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development.." Journal of medicinal chemistry, 2023. https://doi.org/10.1021/acs.jmedchem.3c00623

RethinkPeptides

RethinkPeptides Research Database. "Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permea..." RPEP-06925. Retrieved from https://rethinkpeptides.com/research/guerlavais-2023-discovery-of-sulanemadlin-alrn6924

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.